|More from: | McKinsey |||
There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios.
The passage of US tax reform in late 2017 led to speculation that merger-and-acquisition activity would soon surge among pharmaceutical companies, due in part to tax-cut benefits accruing to sellers. Indeed, that has come to pass: in the first half of 2018, there were 212 deals in the sector worth more than $200 billion, up from 151 such deals in the year-earlier period.1 1.Data are from Dealogic.com. It is important to note that M&A activity as measured by deal value can be volatile and skewed significantly by a single large deal. For instance, the recent announcement of a $62 billion deal between
About | McKinsey |
McKinsey is a global management consulting firm that serves a broad mix of private, public and social sector institutions. We help our clients make significant and lasting improvements to their performance and realize their most important goals. With nearly a century of experience, we’ve built a firm uniquely equipped to this task.
Our work is founded on a rigorous understanding of every client’s institutional context, sector dynamics, and macroeconomic environment. For this reason, we invest more than $600 million of our firm’s resources annually in knowledge development, learning and capability building. We study markets, trends, and emerging best practices, in every industry and region, locally and globally. Our investment in knowledge also helps advance the practice of management. We publish our findings extensively, and we engage with leading thinkers on the most pressing issues facing our clients and society.